Supriya Lifescience
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Supriya Lifescience is poised for stable growth, driven by its diversified product offerings and strategic customer contracts, which enhance revenue visibility. Management has indicated a robust revenue increase, although margins may experience some pressure due to competitive pricing in the Pharma APIs and CRAMS sector. Vista's financial outlook reflects this stability, with revenue growth expected to align with historical performance and margins remaining broadly stable. The company's conservatively financed balance sheet, characterized by low leverage, supports its financial stability and positions it well for future investments. The macro environment in India, marked by improving manufacturing activity and favorable liquidity conditions, further bolsters the outlook for Supriya Lifescience. Over the next 12-24 months, key opportunities include expanding market share through strategic partnerships and leveraging the growing demand for contract manufacturing services. However, watchpoints include potential raw material supply constraints and competitive pressures that could impact margins. Overall, Supriya Lifescience's outlook remains positive, with a target price reflecting a modest expected upside, aligning with Vista's investment recommendation
Why We Like This Stock
- Diversified product offerings enhance revenue visibility and growth potential
- Conservatively financed balance sheet supports financial stability and future investments
- Favorable macro conditions in India bolster manufacturing activity and liquidity
Things To Watch Out For
- Margins may face pressure due to competitive pricing in the Pharma APIs and CRAMS sector
- Potential raw material supply constraints could impact production and profitability
- Increasing competition may challenge market share and pricing power
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 570 | 696 | 828 | 827 | 975 |
| Profit Before Tax (Cr.) | 166 | 248 | 275 | 209 | 271 |
| PBT Margin | 29.1% | 35.6% | 3321.3% | 25.2% | 27.8% |
| Net Profit (Cr.) | 128 | 192 | 213 | 162 | 210 |
| Earnings Per Share | 16.0 | 23.8 | 26.5 | 20.1 | 26.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ▲ Buy | 1,030 | 29-May-2026 |
| Deven Choksey | ► Add | 1,049 | 10-Jun-2026 |
Company Overview
Show Company Profile
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.